gemcitabine has been researched along with deoxyuridine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al Meani, SA; Clausen, AR; Piskur, J | 1 |
| Benyumov, A; Gurvich, VJ; Kirstein, MN; Lis, LG; Williams, BW | 1 |
| Beijnen, JH; Benhadji, KA; Callies, S; Garcia-Ribas, I; Jansen, RS; Koolen, SL; Kronemeijer, RH; Langenberg, MH; Nol, A; Schellens, JH; Slapak, CA; Voest, EE; Witteveen, PO | 1 |
| Dantzig, AH; Durland-Busbice, S; Heinz-Taheny, K; Iversen, PW; Pratt, SE; Shepard, RL | 1 |
| Dantzig, AH; Donoho, GP; Durland-Busbice, S; Perkins, EJ; Pratt, SE; Shepard, RL; Starling, JJ; Wickremsinhe, ER | 1 |
| Benhadji, KA; Makiuchi, T; Nokihara, H; Sekiguchi, R; Slapak, CA; Tamura, T; Uenaka, K; Yamada, Y; Yamamoto, N | 1 |
| Lee, LB; Ruterbories, KJ; Schmalz, CA; Torchia, J; Wickremsinhe, ER | 1 |
| Aguirre, E; Benhadji, KA; Callies, S; Garcia, M; Gil-Martín, M; Llombart, A; Morales, S; Oaknin, A; Salazar, R; Wickremsinhe, ER | 1 |
| Baay, M; Burrows, N; Deschoolmeester, V; Lardon, F; Laukens, K; Meijnders, P; Pauwels, B; Pauwels, P; Peeters, M; Van den Weyngaert, D; Van Gestel, D; Vermorken, JB; Vu, TN; Williams, KJ; Wouters, A | 1 |
| Benhadji, KA; Callies, S; Cohen, RB; Faivre, SJ; Horn, CL; Myrand, SP; Olszanski, AJ; Ouyang, H; Raymond, E; Riess, H; Wang, X; Weigang-Köhler, K; Wickremsinhe, ER | 1 |
4 trial(s) available for gemcitabine and deoxyuridine
| Article | Year |
|---|---|
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prodrugs; Quinazolines; Treatment Outcome; Young Adult | 2011 |
Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Carboxylesterase; Deoxycytidine; Deoxyuridine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Polymorphism, Single Nucleotide; Prodrugs | 2013 |
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Prodrugs; Taxoids; Treatment Outcome | 2014 |
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Prodrugs | 2015 |
6 other study(ies) available for gemcitabine and deoxyuridine
| Article | Year |
|---|---|
Pasteurella multocida thymidine kinase 1 efficiently activates pyrimidine nucleoside analogs.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Deoxyuridine; Escherichia coli; Gemcitabine; Microbial Sensitivity Tests; Pasteurella multocida; Pyrimidine Nucleosides; Thymidine Kinase; Zidovudine | 2010 |
Combinatorial pharmacologic effects of gemcitabine and its metabolite dFdU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combinatorial Chemistry Techniques; Deoxycytidine; Deoxyuridine; Embryo, Nonmammalian; Embryonic Development; Floxuridine; Gemcitabine; Humans; Tumor Stem Cell Assay; Zebrafish | 2011 |
Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Bystander Effect; Carboxylesterase; Deoxycytidine; Deoxyuridine; Female; Gemcitabine; Humans; Hydrolysis; Molecular Structure; Neoplasms; Prodrugs; Recombinant Proteins; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Topics: Administration, Metronomic; Administration, Oral; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxyuridine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression; HCT116 Cells; Humans; Lung Neoplasms; Mice; Prodrugs; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC-MS/MS.
Topics: Antimetabolites, Antineoplastic; Chromatography, Liquid; Deoxycytidine; Deoxyuridine; Floxuridine; Gemcitabine; Humans; Prodrugs; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein.
Topics: Breast Neoplasms; Cell Cycle; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Deoxyuridine; Female; Gemcitabine; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; In Vitro Techniques; Radiation-Sensitizing Agents | 2014 |